In all critical stages in the drug life cycle, BaiPharm can provide specific
recommendations and actionable solutions to clients.
WEBINARS
MORE >
OTC Drug Focus: How to Start and Manage Your Cross-border E-commerce (CBEC) Operations in China
[ Thursday ,3rd November 2022 ]
LATEST NEWS
REGULATION
Law & Regulation
CDE Guideline
Pharmacopoeia
MAH
CMC
Clinical Trial
Bioequivalence (BE)
Innovative Drug
API
Drug Registration
E-commerce
Packaging
Excipient
Monthly Recap: China Pharmaceutical Regulatory Updates | November 2022
Check out China's Pharma Regulatory Updates for November 2022: 1. China NMPA Renews Classifications of Sodium Hyaluronate Products;
2. China NMPA Requires All Drug Registration Application Documents to Be Submitted in Compact Disks; 3. China NMPA Consults on Chemical API Registration Renewal Regulation, and more.
Dec 09, 2022
REGULATION
China Bans a List of Drugs from Online Sales: Vaccines, Anesthetics, and More
The list of drugs banned online in China include vaccines, blood products, anesthetics, psychiatric drugs, toxic drugs for medical use, radioactive drugs, medical precursor chemicals, etc. The list takes effect on Dec. 1, 2022, the same day when the Administrative Measures for Supervising Online Sales of Drugs came into force.
Dec 08, 2022
INDUSTRY
Marketing Approval
Innovative Drug
Generic Drug
Biological Product
Cancer
Cardiovascular Disease
Vaccine
Drug Registration
New Drug
Monthly Report: New Drug Approvals in China | November 2022
In October 2022, China NMPA approved 14 new drugs, including 12 chemical drugs and 2 biological products.
Dec 05, 2022
REGULATION
China Requires Electronic Submission of All Drug Registration Application Documents from Jan. 1, 2023
China NMPA requires that all documents for drug registration applications, as well as supplemental documents sent during the review, shall be submitted electronically in compact disks with no paper required, from Jan. 1, 2023.
Dec 02, 2022
INDUSTRY
